Fonde skyder 320 millioner i dansk biotekselskab

Det 18 måneder gamle biotekselskab Snipr Biome har rejst 320 mio. kr. fra fire danske og udenlandske investorer, der skal hjælpe selskabet i dets forsøg på at finde penicillins afløser.
Christian Elling er som managing partner i Lundbeckfonden Emerge én af investorerne i det danske crispr-selskab Snipr Biome. | Photo: Lundbeckfonden
Christian Elling er som managing partner i Lundbeckfonden Emerge én af investorerne i det danske crispr-selskab Snipr Biome. | Photo: Lundbeckfonden

Lundbeckfonden har sammen med den hollandske LSP, tyske Wellington og danske North-East Family Office (Nefo) investeret 320 mio. kr. i den danske opstartvirksomhed Snipr Biome, der benytter sig af crispr-teknologien til at ramme bakterier.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading